Advanced Solid Tumor Clinical Trials & Research at Providence Medical Group

Advanced solid tumors represent a significant challenge in oncology, characterized by their resistance to conventional therapies and their potential to metastasize, leading to poor prognosis for patients. These tumors are often defined by their stage, typically stage III or IV, indicating local invasion or distant spread. Common types include advanced stages of breast, lung, colorectal, and pancreatic cancers, among others.

Advanced solid tumors studies are a novel design in oncology clinical trials that test the effect of a drug targeting a specific mutation or molecular alteration across multiple cancer types. Unlike traditional clinical trials that focus on a single cancer type, basket studies group patients based on the presence of a particular biomarker, regardless of where the cancer originated in the body.

Key features of these studies include:

  1. Biomarker-driven approach
  2. Multiple cancer types in one trial
  3. Usually single-arm design
  4. Potential for faster drug development

These studies are particularly useful for rare cancers and for evaluating targeted therapies. They can provide valuable insights into the efficacy of a treatment across various tumor types that share a common genetic alteration.

Providence Medical Group is currently enrolling patients for the following advanced solid tumor clinical trials:

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Treatment agent: AZD0901 is a novel antibody-drug conjugate (ADC) targeting Claudin (CLDN) 18.2.
Physician: Ian Anderson, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: Study Details | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

Treatment agent: VMD-928 (oral CNS-penetrant) + selective inhibitor of TrkA
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | ClinicalTrials.gov
Sponsor: VM Oncology, LLC
Location: Providence Cancer Center, Santa Rosa, CA

A study of Dato-Dxd as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumors: AZ D926UC00001 Tropion Pan-Tumor 03.​

Treatment agent: Datopotamab Deruxtecan- an ADC comprised of a recombinant humanized anti-TROP2 IgG1 mAb
Physician: Yao Yao Pollock, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)​

Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center, Santa Rosa, CA

Study for participants with selected HER2 expressing tumors: biliary tract, bladder, endometrial, ovarian, pancreatic, and rare tumors (Destiny Pan-Tumor 2)

Treatment agent: trastuzumab deruxtecan (T-DXd)
Physician: Dr Ian Anderson
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

A Phase 1b/2, Multicenter, OpenLabel Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (EMD Serono MS202329-0010 PROCEADE)

Treatment agent: Anti-CEACAM5 Antibody-Drug Conjugate M9140
Physician: Ian Anderson, MD
Study Coordinator: Aubrey Adiao // aubrey.adiao@providence.org // 707-521-3830
Study Resources: Study Details | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | ClinicalTrials.gov
Sponsor: EMD Serono Research & Development Institute, Inc
Location: Providence Cancer Center, Santa Rosa, CA

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Treatment agent: INBRX-106 (Hexavalent OX40 Agonist)
Physician: Ian Anderson, MD
Study Coordinator: Aubrey Adiao // aubrey.adiao@providence.org // 707-521-3830
Study Resources: Study Details | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | ClinicalTrials.gov
Sponsor: Inhibrx Biosciences, Inc
Location: Providence Cancer Center, Santa Rosa, CA

Phase 1/2 study of rinatabart sesutecan (Rina-S; also known as GEN1184; formerly known as PRO1184) to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Rina-S in patients with locally advanced and/or metastatic solid tumors.

Treatment agent: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) GCT1184-01 (PRO1184-001)
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: Study Details | Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | ClinicalTrials.gov
Sponsor: Genmab
Location: Providence Cancer Center, Santa Rosa, CA

Phase III trial of single fraction stereotactic radiosurgery (SRS) versus fractionated SRS (FSRS) for intact brain metastases

Treatment agent: Fractionated stereotactic radiosurgery (FSRS) to usual care Stereotactic radiosurgery (SRS)
Physician: Michael N. Corradetti, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: Study Details | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | ClinicalTrials.gov
Sponsor: NRG Oncology
Location: Providence Cancer Center, Santa Rosa, CA

Study to Assess the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

Treatment agent: ART0380 + Irinotecan
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | ClinicalTrials.gov
Sponsor: Artios Pharma Ltd.
Location: Providence Cancer Center, Santa Rosa, CA

Phase III trial of single fraction stereotactic radiosurgery (SRS) versus fractionated SRS (FSRS) for intact brain metastases

Treatment agent: Fractionated stereotactic radiosurgery (FSRS) to usual care Stereotactic radiosurgery (SRS)
Physician: Michael N. Corradetti, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: Study Details | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | ClinicalTrials.gov
Sponsor: NRG Oncology
Location: Providence Cancer Center, Santa Rosa, CA

Our Providers

Our Locations